Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT02925117

Public ClinicalTrials.gov record NCT02925117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study was to evaluate the safety and efficacy of multiple doses of upadacitinib monotherapy versus placebo in the treatment of adults with moderate to severe atopic dermatitis (AD).

Study identification

NCT ID
NCT02925117
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
167 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 24, 2016
Primary completion
Aug 9, 2017
Completion
Jan 30, 2019
Last update posted
Jul 15, 2020

2016 – 2019

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
ForCare Clinical Research /ID# 157974 Tampa Florida 33613-1244
Advanced Medical Research /ID# 154516 Sandy Springs Georgia 30328-6141
DermAssociates /ID# 153584 Rockville Maryland 20850
Tufts Medical Center /ID# 153586 Boston Massachusetts 02111
Psoriasis Treatment Ctr NJ /ID# 153578 East Windsor New Jersey 08520
Icahn School of Med Mt. Sinai /ID# 153582 New York New York 10029
Univ Rochester Med Ctr /ID# 154477 Rochester New York 14642
Arlington Research Center, Inc /ID# 154522 Arlington Texas 76011
Modern Research Associates, PL /ID# 154487 Dallas Texas 75231
Center for Clinical Studies /ID# 153589 Houston Texas 77004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02925117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 15, 2020 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02925117 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →